News & Events about Atricure Inc.
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming 41st Annual J.P. Morgan Healthcare Conference...
Business Wire
2 months ago
AtriCure Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced that it has been named a winner of the 2022 Diversity, Equity & Inclusion Award...
Shares of AtriCure, Inc. (NASDAQ:ATRC Get Rating) have earned an average recommendation of Moderate Buy from the eight research firms that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating and three have given a buy rating to the ...
Business Wire
3 months ago
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will present at the 34th Annual Piper Sandler Healthcare Conference. AtriCures...
Ticker Report
4 months ago
AtriCure, Inc. (NASDAQ:ATRC Get Rating) insider Vinayak Doraiswamy sold 4,983 shares of AtriCure stock in a transaction that occurred on Thursday, September 15th. The stock was sold at an average price of $45.99, for a total value of $229,168.17. Following the transaction, the insider now ...